Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Accumulated Expenses: 2017-2024

Historic Other Accumulated Expenses for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $901,000.

  • Crinetics Pharmaceuticals' Other Accumulated Expenses rose 66.42% to $1.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 million, marking a year-over-year increase of 66.42%. This contributed to the annual value of $901,000 for FY2024, which is 72.42% down from last year.
  • Crinetics Pharmaceuticals' Other Accumulated Expenses amounted to $901,000 in FY2024, which was down 72.42% from $3.3 million recorded in FY2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Other Accumulated Expenses peaked at $3.3 million during FY2023, and registered a low of $335,000 during FY2022.
  • For the 3-year period, Crinetics Pharmaceuticals' Other Accumulated Expenses averaged around $1.5 million, with its median value being $901,000 (2024).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 875.22% in 2023, then plummeted by 72.42% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $835,000 in 2020, then rose by 12.46% to $939,000 in 2021, then plummeted by 64.32% to $335,000 in 2022, then skyrocketed by 875.22% to $3.3 million in 2023, then tumbled by 72.42% to $901,000 in 2024.